Compugen to Present at SITC 2025

Rhea-AI Summary

Compugen (Nasdaq: CGEN) will present clinical data from an ongoing first‑in‑human trial of the anti‑IL18BP antibody COM503 (GS‑0321) at the 40th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) on November 7–9, 2025 in National Harbor, Maryland.

The poster (Abstract 589) — titled "A First in human clinical trial to assess the anti‑IL18BP antibody, COM503 (GS‑0321) in Participants with Advanced Solid Malignancies" — will be presented by Dr. Manish Sharma on Friday, November 7, 2025. The company described COM503 as part of an ongoing trial in participants with advanced solid malignancies.

HOLON, Israel, Oct. 6, 2025 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in predictive computational target discovery, powered by AI/ML today announced, that a trial in progress of the first in human clinical trial to assess the anti-IL18BP antibody, COM503 (GS-0321) in participants with advanced solid malignancies will be presented at the 40^th Annual Meeting of the Society for Immunotherapy of Cancer (SITC), taking place between November 7-9, 2025, in National Harbor, Maryland.

Poster presentation details:
Abstract Title: A First in human clinical trial to assess the anti-IL18BP antibody, COM503 (GS-0321) in Participants with Advanced Solid Malignancies
Abstract number: 589
Presenter: Dr. Manish Sharma, MD, Co-Director of Clinical Research, START Midwest, Grand Rapids
Date: Friday, November 7, 2025

About Compugen
Compugen is a clinical-stage therapeutic discovery and development company utilizing its broadly applicable predictive AI/ML powered computational discovery platform (Unigen^™) to identify new drug targets and biological pathways for developing cancer immunotherapies. Compugen has two proprietary product candidates in Phase 1 development: COM701, a potential first-in-class anti-PVRIG antibody and COM902, a potential best-in-class antibody targeting TIGIT for the treatment of solid tumors. Rilvegostomig, a PD-1/TIGIT bispecific antibody where the TIGIT component is derived from Compugen's clinical stage anti-TIGIT antibody, COM902, is in Phase 3 development by AstraZeneca through a license agreement for the development of bispecific and multispecific antibodies. GS-0321 (previously COM503), a potential first-in-class, high affinity anti-IL-18 binding protein antibody, which is in Phase 1 development, is licensed to Gilead. In addition, the Company's therapeutic pipeline of early-stage immuno-oncology programs consists of research programs aiming to address new mechanisms to activate the immune system against cancer. Compugen is headquartered in Israel, with offices in San Francisco, CA. Compugen's shares are listed on Nasdaq and the Tel Aviv Stock Exchange under the ticker symbol CGEN.

Company contact:
Yvonne Naughton, Ph.D.
Vice President, Head of Investor Relations and Corporate Communications
Email: ir@cgen.com
Tel: +1 (628) 241-0071 

View original content:https://www.prnewswire.com/news-releases/compugen-to-present-at-sitc-2025-302575665.html

SOURCE Compugen Ltd.

FAQ

When will Compugen (CGEN) present COM503 data at SITC 2025?

The poster will be presented on Friday, November 7, 2025 during SITC 2025 (Nov 7–9).

What is the title and abstract number for Compugen's SITC 2025 presentation (CGEN)?

Abstract 589: "A First in human clinical trial to assess the anti‑IL18BP antibody, COM503 (GS‑0321) in Participants with Advanced Solid Malignancies."

Who is presenting Compugen's COM503 poster at SITC 2025 (CGEN)?

The poster will be presented by Dr. Manish Sharma, MD, Co‑Director of Clinical Research, START Midwest, Grand Rapids.

What clinical trial stage is Compugen's COM503 (GS‑0321) program (CGEN)?

COM503 is being evaluated in an ongoing first‑in‑human clinical trial in participants with advanced solid malignancies.

Will Compugen disclose efficacy or safety results for COM503 at SITC 2025 (CGEN)?

The announcement confirms a poster presentation of trial data but does not specify the content scope; attendees should consult the poster (Abstract 589) for details.